Expression of Syndecan-2 in gastric adenocarcinoma and its effect on tumorigenesis in vitro

Jingwen Wang1, Chen Lu2, Jiayan Chen1, Xi Chen1, Shiwen Wang3,4,5, Xingang Lu6, Xi Tang1

1Department of Oncology, 2Department of Pathology, 3Department of Laboratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China; 4Key Laboratory of Clinical Geriatric Medicine, Shanghai 200040, China; 5Research Center on Aging and Medicine, Fudan University, Shanghai 200040, China; 6Department of Traditional Chinese Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China

Contributions: (I) Conception and design: J Wang; (II) Administrative support: X Tang; (III) Provision of study materials or patients: C Lu; (IV) Collection and assembly of data: J Wang, J Chen; (V) Data analysis and interpretation: X Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Xi Tang. Department of Oncology, Huadong Hospital Affiliated to Fudan University, No. 221 West Yan’an Road, Shanghai 200040, China. Email: olivia9tang@126.com.

Background: Syndecan-2 (Sdc2) can affect the behavior of some cancer cells. However it is poorly understood in terms of its role in tumorigenesis of gastric carcinoma. The present study was undertaken to explore the expression and prognostic role of Sdc2 in patients with gastric adenocarcinoma tissue, and its effect on tumorigenesis in vitro.

Methods: Sdc2 expression in 46 tissue samples of gastric adenocarcinoma was analyzed by immunohistochemistry. We evaluated the clinical characteristics and survival time. The expression of Sdc2 in gastric carcinoma cell lines was confirmed by real time polymerase chain reaction (RT-PCR) and western blot. Cell migration and invasion assays were carried out to investigate whether the decreased Sdc2 by siRNA transfection affected the tumorigenesis of gastric carcinoma cells.

Results: The results showed that Sdc2 was expressed in tumor tissues and its expression intensity was significantly correlated with invasive and metastatic tendency (P<0.05), but not associated with prognosis (P>0.05). Through in vitro experiments, we proved that down-regulation of Sdc2 with siRNA diminished Sdc2-induced cell migration and invasion in SGC-7901 gastric carcinoma cells.

Conclusions: These results suggested regulatory effects on migration and invasion by Sdc2 in gastric carcinoma cell. The up-regulation of Sdc2 expression in cancer tissue might play an important role in cancer progression of gastric adenocarcinoma.

Keywords: Syndecan-2 (Sdc2); gastric adenocarcinoma; clinicopathological characteristics; migration; invasion

Submitted May 25, 2017. Accepted for publication Jul 24, 2017.
doi: 10.21037/tcr.2017.08.04
View this article at: http://dx.doi.org/10.21037/tcr.2017.08.04

Introduction

Syndecans belong to the family of transmembrane heparan-sulfate proteoglycans, composed of 4 members, Syndecans-1, -2, -3 and -4. Syndecan-2 (Sdc2) is a kind of transmembrane protein with molecular mass of 21 kDa. Its core protein is composed of three domains: the ectodomain containing multiple attachment sites for heparan sulfate side-chains, a single transmembrane domain and a cytoplasmic domain with two highly conserved regions (C1, C2) and a variable region (V) (1).

Sdc2 is mainly expressed by fibroblasts and endothelial cells. Being a co-receptor of growth factor and cytokine (VEGF, TGF-β, interleukin-8 et al.) (2,3), Sdc2 can modulate cell adhesion and migration through certain signaling pathway (4,5). Expressed by microvascular
endothelial cells Sdc2 is vital for angiogenesis both in normal and tumor tissues. The shed form of Sdc2 ectodomain can restrain angiogenesis obviously by inhibiting endothelial cell migration in the presence of VEGF. This effect is demonstrated to be mediated by protein tyrosine phosphatase receptor CD148, which leads to a reduction in active β1 integrins on endothelial cells (6). In addition to participation in cell-cell interactions, Sdc2 also mediates cell-extracellular matrix interactions as a cell-surface receptor. During zebrafish embryonic development, Sdc2 which expressed in extra-embryonic tissues regulates fibronectin and laminin matrix assembly, promoting organ primordia migration and fibrillogenesis (7). Although previous studies focused on the roles of Sdc2 in normal cells adhesion and signaling, recently its function of accelerating tumor growth and metastasis has attracted more attention. It has been confirmed to be up regulated in some cancer cells such as breast, pancreatic, colorectal and prostate carcinomas (8-11). Altered expression of Sdc2 can affect migration and invasion of these cancer cells. Lim et al. recently found that depletion of Sdc2 by siRNA could reduce invasion activity of breast carcinoma cell line MDA-MB231 by regulating the RhoGTPases (8). Vicente et al. demonstrated that Sdc2 expression was enhanced by stromal fibroblasts in highly metastatic colorectal cancer cell line, HCT-116. A decrease in HCT-116 cell adhesion, migration, and organization of actin filaments was due to the blocking Sdc2 by a specific antibody (10).

It is clear that Sdc2 can affect the behaviors of some cancer cells. However it is poorly understood in terms of its role in tumorigenesis of gastric carcinoma. Here we conducted retrospective studies on patients with gastric adenocarcinoma and attempted to determine the expression and prognostic role of Sdc2. Besides, in vitro experiments clarified how Sdc2 affected the biological behaviors of gastric adenocarcinoma cells.

Methods

Patients and tissue sampling

The specimens of gastric adenocarcinoma used in this study were obtained from surgical procedures. Forty-six patients underwent radical gastrectomy for gastric adenocarcinoma at Department of Surgery, Huadong Hospital affiliated to Fudan University, between 2010 and 2013. None of the patients was treated with neoadjuvant therapy. The age range was 32–82 years (average: 64 years), including 32 men and 14 women. One case of tumor was located at pyloric, 7 cases at cardia, 13 cases at gastric antrum, 20 cases at gastric body and 5 cases at gastric fundus. The tumor-node-metastasis (TNM) classification was assigned by the pathologist according to the criteria of the American Joint Committee on Cancer (7th ed, 2010) (12). Two (4.35%) patients had stage T0, 1 (2.17%) stage T1, 3 (6.52%) stage T2, 6 (13.04%) stage T3 and 34 (73.92%) had stage T4 disease. Thirty-two (69.57%) patients had metastases in regional lymph nodes. No one had distant metastases. The adjacent normal tissues were used as control. Median follow-up was 31 months (IQR, 21.1–45.6). Disease-free survival (DFS, defined as the time from curative treatment to the date of disease recurrence or death due to disease progression). Overall survival (OS, defined as the time from curative treatment to the death from any cause).

Immunohistochemistry staining and evaluation

Specimens were fixed in 4% buffered formalin, embedded in paraffin, cut at 2.5 μm thickness. Sections were deparaffinized, alcohol hydrated, heat-induced epitope retrieved and endogenous peroxidase inactivated in sequence. Then primary antibody for Sdc2 (dilution 1:50; Life Span BioSciences, Inc., USA) was added to the sections. Afterwards sections were incubated for 2 hours at room temperature. After washing in PBS for three times, sections were incubated with EnVision kit (DAKO Corp., Denmark) for 30 minutes at 37 °C. Stained with diaminobenzidine (DAKO Corp., Denmark), sections were counterstained with Mayer’s hematoxylin and mounted. For a negative control, staining was performed without the primary antibody. Results of slides were assessed by two pathological doctors in a double-blind method. Staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The percentage of positive cells were divided into 0 (no positive cell), 1 (≤25%), 2 (26–50%), 3 (51–75%), 4 (>75%). According to the product of staining intensity and the percentage of positive cells, the immunohistochemical result was classified as negative-low expression (<4) and moderate-strong expression (≥4).

Cell cultures

Human gastric carcinoma cell lines MKN-45, MGC-803, BGC-823 and SGC-7901 were obtained from Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). All cells were maintained in RPMI1640 (Gibco
expression of Sdc2 was detected in neoplastic tissues and normal tissues. In normal gastric tissues, moderate-to-strong staining for Sdc2 was observed in endothelial cells and fibroblasts, but negative in epithelial cells (Figure 1A). On the contrary, Sdc2 expression was significantly higher in neoplastic tissues than in normal tissues.
obviously increased in neoplastic tissues compared with normal tissues (Figure 1B,C).

**The high expression of Sdc2 in tumor tissues is correlated with some aggressive pathological features**

To explore the function of Sdc2 in tumor tissues, we analyzed the association between the expression of Sdc2 and clinicopathologic characteristics. According to expression intensity (refer to immunohistochemical staining and evaluation) 14 (30.43%) sections with negative-low expression (<4) were designated as Group A, and 32 (69.57%) sections with moderate-strong expression (≥4) were designated as Group B. Immunohistochemical reaction was cytoplasmatic. As shown in Table 1, rates of local deep invasion (P=0.03), neural invasion (P=0.035) and lymph node metastasis (P=0.009) were significantly higher in Group B than those were shown in Group A. There was no correlation between Sdc2 expression, tumor size (P=0.246), tumor differentiation (P=0.2) and tumor thrombosis (P=0.559). These results suggested that the expression of Sdc2 was associated with aggressive biological behaviors of gastric adenocarcinoma.

**Overexpression of Sdc2 in tumor tissues leads to shortened survival**

To investigate whether the expression intensity of Sdc2 was correlated with survival period, we followed up these 46 patients and analyzed survival time. Median DFS and OS in Group B was 19.0 months (95% CI, 5.9–32.1) and 28.7 months (95% CI, 17.1–40.3) respectively, but neither had reached in Group A. Analysis of survival showed that patients with moderate-strong expression of Sdc2 had a trend toward decreased DFS (P=0.142; Figure 2A) and OS (P=0.068; Figure 2B). There was no significant differences in rates of 2-year DFS (71.43% vs. 46.88%; P=0.224) and OS (85.71% vs. 53.13%; P=0.076) between two groups. Accordingly, the trends of shortened survival and low survival rate indicated that up-regulation of Sdc2 expression might predict adverse clinical outcome.

**Expression levels of Sdc2 in different gastric carcinoma cell lines**

In order to detect the expression levels of Sdc2 in different gastric carcinoma cell lines, RT-PCR experiments were carried out and revealed that the human gastric carcinoma cell lines BGC-823, MGC-803 and SGC-7901 expressed Sdc2 mRNA (Figure 3A,B) except MKN-45 cells. Western-blot analysis was performed to detect expression of Sdc2 protein (Figure 3C) and proved that it could be detected only in SGC-7901 cells. Based on the above results, SGC-7901 cells were elected for the following experiment.

Afterwards, we proved that Sdc2 expression in SGC-7901 cells was significantly decreased using Sdc2 siRNA (Figure 4).

**Sdc2 suppression inhibits cell migration and invasion in vitro**

To determine the biological role of Sdc2 expression in migration/invasion of gastric carcinoma cells, we examined the migration and invasion activity of SGC-7901 cells using transwell assays. Compared with cells transfected with...
Table 1 Relationship between clinicopathological characteristics and expression of Sdc2

<table>
<thead>
<tr>
<th>Item</th>
<th>Sdc2 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group A (n=14)</td>
<td>Group B (n=32)</td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>5 (35.71)</td>
<td>18 (56.25)</td>
</tr>
<tr>
<td>Medium/high</td>
<td>9 (64.29)</td>
<td>14 (43.75)</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>4 (28.57)</td>
<td>15 (46.88)</td>
</tr>
<tr>
<td>&lt;5</td>
<td>10 (71.43)</td>
<td>17 (53.12)</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T0–T2</td>
<td>5 (35.71)</td>
<td>1 (3.13)</td>
</tr>
<tr>
<td>T3–T4</td>
<td>9 (64.29)</td>
<td>31 (96.87)</td>
</tr>
<tr>
<td>Neural invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>8 (57.14)</td>
<td>8 (25.00)</td>
</tr>
<tr>
<td>Positive</td>
<td>6 (42.86)</td>
<td>24 (75.00)</td>
</tr>
<tr>
<td>Tumor thrombosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>10 (71.43)</td>
<td>20 (62.50)</td>
</tr>
<tr>
<td>Positive</td>
<td>4 (28.57)</td>
<td>12 (37.50)</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>8 (57.14)</td>
<td>6 (18.75)</td>
</tr>
<tr>
<td>Positive</td>
<td>6 (42.86)</td>
<td>26 (81.25)</td>
</tr>
</tbody>
</table>

Sdc2, Syndecan-2.

Figure 2 Impact of Sdc2 expression in gastric cancer tissues on disease-free survival (A) and overall survival (B). Sdc2, Syndecan-2.
non-targeting control siRNA, migration ability of SGC-7901 cells which were transfected with Sdc2-siRNA was decreased obviously (Figure 5). Cell invasion ability was also significantly restrained after Sdc2 expression was suppressed by siRNA (Figure 6). These data suggested that Sdc2 could regulate cell migration and invasion in gastric carcinoma cells.

**Discussion**

Increasing number of findings have confirmed that Sdc2 plays an important role in the development and progression of tumor. The expression level of Sdc2 is up-regulated in certain tumor tissues. In our study, Sdc2 expression and relationship with clinicopathological characteristics and disease prognosis were assessed in a cohort of 46 patients treated with radical gastrectomy for gastric adenocarcinoma. Immunohistochemistry results demonstrated that in addition to endothelial cells and fibroblasts, Sdc2 was also found in the majority of tumor cells, but negative in epithelial cells of normal gastric tissues. Further *in vitro* experiments had shown that the human gastric carcinoma cell line SGC-7901 expressed both Sdc2 mRNA and protein. The above results were consistent with previous findings where Sdc2 expression was enhanced in colorectal cancer tissues both *in vivo* and *in vitro* (13,14). Therefore, we speculate that Sdc2 up-regulated expression is a common phenomenon of gastrointestinal malignancy.

Furthermore, correlation was found between the expression of Sdc2 in tumor tissues and disease prognosis. In Popović’s study (11), 86 prostate cancer patients treated with radical prostatectomy were assessed. Immunohistochemical staining results showed that normal prostatic epithelial tissue and stroma did not express Sdc2. To the contrary, Sdc2 expression was present in the majority of prostate cancers (76.1%). There was a notable correlation between Sdc2 overexpression in prostate cancer and established features indicative of worse prognosis. Similar findings were reported in the study of colorectal cancer that overexpression of Sdc2 was associated with pathological features of poor prognosis (13). Our results on Sdc2 expression in gastric adenocarcinoma were consistent with
these earlier reports. A moderate-strong Sdc2 expression in tumor lesion was associated with high probability of local deep infiltration, neural invasion, and lymph node metastasis. Although there was no significant difference in survival analysis between two groups, partially due to small sample size and the interference of different adjuvant therapy regimens, we found patients with moderate-strong expression of Sdc2 had a trend toward decreased DFS and OS. Therefore, our results supported the potential role of Sdc2 as a prognostic factor.

How does Sdc2 promote the process of tumor growth and progression? There are two main mechanisms according to the results of previous researches. First, Sdc2 was able to strengthen motility and increase invasion ability of cancer cells. Under physiological conditions, its cytoplasmic domain C1 could interact with proteins of the ERM family (ezrin, radixin, and moesin) (15). These proteins were one of the key molecules which linked the actin cytoskeleton to the plasma membrane and were implicated in cells including cancer cells morphogenesis, migration and adhesion (16,17). During cancer progression, Sdc2 promoted migration and metastasis through certain
cellular signal transduction pathways. In study of breast carcinoma cell line MDA-MB231, it was proved that depletion of Sdc2 gave rise to the decline of invasiveness, reducing cell migration accompanied by translocation of p190ARhoGAP to the cell edge and its increased tyrosine phosphorylation (8). TGFβ/Smad2 was another signal pathway that got involved in. By using its transmembrane heparan sulfate chains, Sdc2 interacted with members of the TGFβ superfamily (7). It was demonstrated that there was a positive feedback mechanism between Sdc2 expression and TGFβ signaling in fibrosarcoma cells. In Sdc2-deficient fibrosarcoma cells, TGFβ2-dependent up-regulation of Smad2 phosphorylation level was suppressed, subsequently its downstream transcriptional regulation of integrin β1 was dramatically inhibited leading to the alteration of adhesion (18). In our study, down-regulation of Sdc2 inhibited SGC-7901 cell migration and invasion. Agreed with previous studies, we proved that Sdc2 had a strong effect on maintaining an invasive phenotype of gastric carcinoma cells.

In addition to its roles in cell adhesion and migration, Sdc2 is necessary for tumor angiogenesis that promotes tumor growth and metastasis. Several studies have shown that Sdc2 could physically interact with cell-cell signaling molecules that stimulated angiogenesis (e.g., VEGF, bFGF) (2,19). These pro-angiogenic growth factors have been illustrated to induce Sdc2 shedding from brain microvascular endothelial cells and then facilitate angiogenesis of gliomas in vitro (20).

There are abundant evidences to demonstrate that Sdc2 can promote the development and progression of certain malignant tumors, but the mechanism is not completely clear. The results presented in this study suggest that Sdc2 plays a crucial role in the migration and invasion of gastric carcinoma cells. The expression of Sdc2 in gastric adenocarcinoma tissues is up-regulated and has the potential to be a prognostic factor for patients with gastric cancer. Further investigations will be required to clarify the mechanism how Sdc2 stimulates tumorigenesis and metastasis in gastric cancer.

Acknowledgements

The authors are grateful to Prof. Jian-Wen Liu and Ms Cen Qiu (State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China) for instruction, and grateful to Dr. Qi Lu (Department of Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China) for providing specimens of gastric adenocarcinoma.

Funding: This study was funded by Shanghai Municipal Commission of Health and Family Planning, “Scientific research project” (No. 20164Y0134) and Shanghai Municipal Commission of Health and Family Planning, Key developing disciplines (No. 2015ZB0501).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards and written informed consent was obtained from all patients.

References


